According to Jain and al., the continuous delivery of methotrexate–transferrin conjugates was attained by virtue of the overexpressed transferrin receptors on the surface of tumor cells, and the results of both in vivo and in vitro assays highlighted the efficiency of the conjugated system when compared to controls [102]. This evidence concerns the gene TFRC and neoplasm.